{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059097","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.061352+00:00","generated_at":"2026-06-02T01:03:35.176148+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Acrivon Q1 net loss $16.5M; ACR-368 Phase 2b 50% ORR; $130M PIPE","bullets":["Net loss $16.5M vs $12.8M YoY; R&D $11.5M, G&A $6.2M.","ACR-368 Phase 2b: 50% confirmed ORR in OncoSignature-positive patients (10) vs 0% in negative (16), p=0.0038.","Endometrial cancer identified as new AP3-predicted sensitive tumor type; median DoR not yet reached.","ACR-2316 IND expected Q3 2024; Phase 1 start Q4 2024.","Closed oversubscribed $130M private placement at premium; cash ~$240M pro forma into H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059097","json":"https://secwatch.observer/filing/0000950170-24-059097.json","markdown":"https://secwatch.observer/filing/0000950170-24-059097.md","text":"https://secwatch.observer/filing/0000950170-24-059097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024059097/0000950170-24-059097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024059097/acrv-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:03:35.176148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aeae7368dec17da42e4ec1b7fd8978ee6a34b634","claim":"Acrivon Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $16.5 million.","evidence_excerpt":"Net loss for the quarter ended March 31, 2024 was $16.5 million compared to a net loss of $12.8 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024059097/0000950170-24-059097-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$16.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}